



**HAL**  
open science

## **Jun and JunD-dependent functions in cell proliferation and stress response**

Erwin Wagner, Arabella Meixner, Florian Karreth, Lukas Kenner, Josef M  
Penninger

► **To cite this version:**

Erwin Wagner, Arabella Meixner, Florian Karreth, Lukas Kenner, Josef M Penninger. Jun and JunD-dependent functions in cell proliferation and stress response. Cell Death and Differentiation, 2010, n/a (n/a), pp.n/a-n/a. 10.1038/cdd.2010.22 . hal-00519207

**HAL Id: hal-00519207**

**<https://hal.science/hal-00519207>**

Submitted on 19 Sep 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **Jun and JunD-dependent functions in cell proliferation and stress response**

Arabella MEIXNER<sup>a</sup>, Florian KARRETH<sup>b</sup>, Lukas KENNER<sup>c</sup>, Josef M. PENNINGER<sup>a</sup>  
and Erwin F. WAGNER<sup>d,#</sup>

<sup>a</sup>Institute of Molecular Biotechnology (IMBA),  
Dr. Bohr-Gasse 3, A-1030 Vienna, Austria

<sup>b</sup>Cancer Research UK Cambridge Research Institut, Li Ka Shing Centre. Robinson Way.  
Cambridge. CB2 0RE United Kingdom

<sup>c</sup>Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Währingerstraße 13a,  
1090 Vienna, Austria; Medical University, Institute of Clinical Pathology,  
Währingergürtel 18-20, A-1090 Vienna.

<sup>d</sup> BBVA-Foundation-CNIO Cancer Cell Biology Programme, Centro Nacional de  
Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro 3, E-28029 Madrid, Spain.

<sup>#</sup>Correspondence should be addressed to:

Erwin F. Wagner, BBVA Foundation – CNIO Cancer Cell Biology Programme, Centro  
Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro, 3, E-28029  
Madrid, Spain.

e-mail: ewagner@cni.es; Tel. +34 917 328 000 Fax: +34 912 246 980

Key words: Jun/AP-1 substitution, development, MEFs, fetal liver, EGFR signaling,  
oxidative stress

Running title: Jun and JunD in development and stress responses

## Abstract

Jun is essential for fetal development, as fetuses lacking Jun die at mid-gestation with multiple cellular defects in liver and heart. Embryos expressing JunD in place of Jun (*Jun<sup>d/d</sup>*) can develop to term with normal fetal livers, but display cardiac defects as observed in fetuses lacking Jun. *Jun<sup>d/d</sup>* MEFs exhibit early senescence, which can be rescued by EGF and HB-EGF stimulation, probably through activation of Akt signaling. Thus, JunD can not functionally replace Jun in regulating fibroblast proliferation.

In *Jun<sup>-/-</sup>* fetal livers increased H<sub>2</sub>O<sub>2</sub> levels are detected and expression of *Nrf1* and *Nrf2* (nuclear erythroid 2-related transcription factors) is down regulated. Importantly, increased oxidative stress as well as expression of *Nrf1* and *Nrf2* is rescued by JunD in *Jun<sup>d/d</sup>* fetal livers. These data demonstrate that Jun is of critical importance for cellular protection against oxidative stress in fetal livers and fibroblasts and Jun-dependent cellular senescence can be restored by activation of the EGFR pathway.

## Introduction

The Jun members - Jun, JunB and JunD - belong to a family of related molecules, which together with the Fos proteins (Fos, FosB, Fra1 and Fra2) and members of the ATF and CREB families, dimerize to form AP-1 complexes<sup>1, 2</sup>. As a result, specific AP-1 complexes activate or repress transcriptional responses to control cell proliferation, differentiation and death<sup>3</sup>.

Jun-deficient embryos die at embryonic day 12.5 (E12.5) with abnormalities in liver and heart<sup>4, 5</sup>. Hepatocyte-specific deletion of Jun in adult livers affects cell survival and cell-cycle progression<sup>6</sup> and Jun cooperates with carcinogens to induce hepatocellular carcinomas<sup>7</sup>. Impaired p21-dependent liver regeneration was shown in livers lacking Jun<sup>8</sup>. Furthermore, mice lacking Jun in hepatocytes display increased hepatotoxicity upon Concanavalin A treatment<sup>9</sup>. This is likely caused by increased oxidative stress, since it can be rescued pharmacologically by nitric oxide (NO) delivery to the liver.

Mice lacking JunD are viable<sup>10</sup>, but show enhanced cardiomyocyte apoptosis and fibrosis<sup>11</sup>, develop chronic kidney disease<sup>12</sup> and exhibit increased bone formation<sup>13</sup>. JunD regulates genes involved in the antioxidant defense and H<sub>2</sub>O<sub>2</sub> production, and exhibits angiogenesis by controlling *VEGF* transcription<sup>14</sup>. Furthermore, a key role for JunD in metabolism and oxidative stress was described, since JunD can modulate insulin/IGF-1 signaling and longevity<sup>15</sup>.

Mice expressing a variant of Jun, in which the JNK (Jun N-terminal kinases) phosphoacceptor sites were mutated to alanines (Jun<sup>AA</sup>) are viable, although they are smaller than wild-type littermates<sup>16</sup>. Mice having Jun replaced by JunB develop to birth, indicating that JunB can substitute for Jun during embryonic development<sup>17</sup>. On the other

hand, JunB-deficient embryos die at E8.5-10.5 due to multiple defects in extra-embryonic tissues<sup>18</sup>. Moreover, JunB was found to be a critical player in endothelial cell morphogenesis by regulating expression of core-binding factor  $\beta$ CBF $\alpha$  and VEGF suggesting that embryonic lethality of JunB-deficient embryos is likely due to a failure in hypoxia-mediated placentation and angiogenesis<sup>19,20</sup>.

Jun is able to suppress p53 gene transcription and *Jun*<sup>-/-</sup> mouse embryonic fibroblasts (MEFs) have increased expression of p53<sup>21</sup>, a severe proliferation defect, undergo premature senescence and are sensitive to p53-induced growth arrest upon UV irradiation<sup>5, 21-23</sup>. JunD also interacts with the p53 pathway as *Jund*<sup>-/-</sup> MEFs exhibit a proliferation defect, which is less severe than that of *Jun*<sup>-/-</sup> cells and is likely caused by increased *p19ARF* expression<sup>24</sup>. Jun also stimulated cell cycle progression through induction of *cyclin D1* transcription<sup>25</sup> and expression of cyclin D1 is down regulated in *Jun*<sup>-/-</sup> MEFs<sup>21, 22</sup>. Immortalized *Jund*<sup>-/-</sup> cells show increased proliferation likely as a consequence of increased *cyclin D1* expression<sup>24</sup>. Overexpression of JunD in immortalized 3T3 cells and T cells resulted in reduced proliferation suggesting that JunD is a negative regulator of proliferation<sup>26,27</sup>.

The Nrf transcription factors are important regulators of cellular redox homeostasis through their capacity to induce the expression of reactive oxygen species (ROS) detoxification enzymes and other antioxidant proteins. Similar to Jun-deficient embryos, Nrf1 null embryos die around E13.5 of embryonic development and display small livers, probably due to the failure in antioxidant gene expression and increased apoptosis<sup>28</sup>. Moreover, ES cells deficient in Nrf1 do not contribute to adult livers in chimeras<sup>28</sup>. In contrast, Nrf2 - similar to JunD - is dispensable for mouse development<sup>29</sup>,

and Nrf2 is involved in G2/M cell cycle block and controls Akt activity<sup>30</sup>. Adult livers lacking Nrf2 display reduced Jun levels<sup>29, 31</sup>, exhibit impaired liver regeneration and oxidative stress<sup>32</sup>. Nrf2-deficient mice are sensitive to chemical-induced acute respiratory distress syndrome<sup>33</sup> and hepatotoxicity<sup>34, 35</sup>, and to liver carcinogenesis<sup>36</sup>. Furthermore, Nrf2 plays a role in age-related diseases, such as neurodegeneration, chronic inflammation, and cancer<sup>37, 38</sup>. Interestingly, fibroblast proliferation was not affected neither by the loss of Nrf1 or Nrf2<sup>28</sup>, although double mutant *Nrf1-Nrf2* MEFs enter early senescence, possibly due to increased p53 levels and severe oxidative stress<sup>28</sup>.

Here we show that JunD can substitute for Jun during fetal development, although embryos display cardiac defects similar to fetuses lacking Jun. Increased H<sub>2</sub>O<sub>2</sub> production and down-regulation of *Nrf1* and *Nrf2* expression of Jun-deficient fetal livers was also rescued by JunD. It appears that Jun and JunD can protect cells and tissues by regulating detoxification and antioxidant genes as was reported for Nrf1/Nrf2<sup>39</sup>. *Jun*<sup>d/d</sup> MEFs displayed impaired proliferation, early senescence and impaired Akt signaling, reminiscent of cells lacking Jun. Aberrant proliferation and senescence of *Jun*<sup>d/d</sup> MEFs was abolished by high levels of EGF or HB-EGF, but these treatments had no effect on cells lacking Jun. Thus, in contrast to JunB, JunD cannot functionally replace Jun in fibroblast proliferation, but has the potential to rescue mouse development to birth.

## Results

### Generation of JunD knock-in mice

A  $Jun^{JunD}$  ( $Jun^{d/+}$ ) knock-in allele was generated to disrupt expression of the endogenous Jun gene allowing simultaneous expression of the complete coding region of JunD. Correctly targeted ES cell clones were identified by PCR and verified by Southern blot analysis (Figure 1A, B). Heterozygous offspring were crossed to a general deleter-Cre to remove the floxed PGK $\beta$ geo selection cassette (Figure 1A), which encodes a neolacZ fusion protein. Heterozygous  $Jun^{d/+}$  offspring were intercrossed to obtain homozygous  $Jun^{d/d}$  embryos (Figure 1C).

To test whether the described targeting event replaced Jun with the JunD coding region,  $Jun^{d/+}$  mice were crossed with  $Jun^{d/-}$  mice. Analysis of 3-week old  $Jun^{d/+}Jun^{d/-}$  mouse tissues and various organs, prepared from E12.5 embryos, showed *JunD* expression where Jun is normally expressed (Figure 1D and data not shown). There was no change in *Junb* expression. Thus, the JunD knock-in allele is expressed with a pattern similar to the endogenous *Jun* gene.

### JunD partially rescues the embryonic lethality of Jun-deficient embryos

35% of homozygous  $Jun^{d/d}$  mice were born (Figure 2A, Table 1A). The remaining 65% died between E12.5 and E13.5 due to defects in the neural tube region and/or a complete delay of development (Figure 2B; Table 1A and data not shown).  $Jun^{d/d}$  newborns displayed open eyes (Figure 2A, C) and died within the first hours after birth. Thus, JunD can with limited efficiency rescue  $Jun^{-/-}$  embryonic lethality up to birth.

Histological analysis of E18.5 embryos and newborns showed that the separation of the cardiac outflow tract into aorta and pulmonary artery had not occurred (Figure 2D, E18.5 and data not shown). This persistence of the heart defect resembling 'persistent truncus arteriosus' likely contribute to the early postnatal lethality of newborns. *Jun<sup>d/d</sup>* embryos displayed normal liver architecture throughout development (Figure 2E and data not shown). In agreement with normal liver pathology of *Jun<sup>d/d</sup>* embryos, there was no difference in proliferation and apoptosis of wild-type and *Jun<sup>d/d</sup>* E12.5 fetal liver cells (Figure 2F and data not shown). Ki67 staining revealed comparable numbers of proliferating cells in wild-type and *Jun<sup>d/d</sup>* fetal livers at E12.5 (Figure 2G). However, increased gene dosage of JunD might be crucial for developmental phenotypes and lethality of *Jun<sup>d/d</sup>* newborns. Indeed, *Jun<sup>d/d</sup>Jun<sup>d/-</sup>* embryos were severely growth retarded and did not develop beyond E13 of development (Figure 2H, Table 1B). Together, these data indicate that JunD expressed from the Jun locus is not sufficient for normal embryonic development.

### **Premature senescence of *Jun<sup>d/d</sup>* MEFs**

We next analyzed whether JunD can substitute for Jun in regulating proliferation of MEFs. Expression of JunD in *Jun<sup>d/d</sup>* MEFs was induced similarly to the endogenous Jun gene (data not shown). Moreover, like *Jun<sup>-/-</sup>* cells, *Jun<sup>d/d</sup>* cells exhibited growth arrest after two to three passages (Figure 3A). Senescence was further confirmed by intense  $\beta$ -galactosidase activity in *Jun<sup>d/d</sup>* MEFs compared to wild-type cells (Figure 3B). Increased levels of JunD were not the cause of the proliferation defect, as *Jun<sup>d/d</sup>* cells lacking endogenous JunD (*Jun<sup>d/d</sup>Jun<sup>d/-</sup>*) also failed to proliferate *in vitro* and underwent

premature senescence (Figure 3C, D). Thus, JunD can not substitute for Jun in the regulation of proliferation in MEFs.

JunD was able to replace c-Jun in repressing p53 transcription, since p53-mediated transactivation (Figure 3E) and p53 mRNA and protein expression were comparable to wild-type MEFs (Figure 3F, G). Analyzing p53 target genes *mdm2*, *p21* and *bax1* upon UV-induction (40J) did not reveal any difference between wild-type and *Jun<sup>d/d</sup>* MEFs (Figure 3H). Furthermore, p53 and p21 protein levels were similar upon UV-treatment indicating that JunD is capable of suppressing p53 transcription (Figure 3H). *Jun<sup>d/d</sup>* MEFs were analyzed for Cdc2, another Jun-dependent cell cycle regulator, and expression was found to be rescued to wild-type levels (Figure 3I). A Jun binding site (PF-1, TGA G TCT) has been described for the mouse *p53* promoter<sup>21, 40</sup>. Chromatin immunoprecipitation (ChIP) experiments showed that both JunD and Jun, but not JunB, efficiently bound the p53 domain in wild-type cells, whereas the binding for Jun was almost undetectable in *Jun<sup>-/-</sup>* and *Jun<sup>d/d</sup>* MEFs (Figure 3L). Moreover, in addition to decreased *cyclin D1* transcription (Figure 3K), the *cyclin D1*-promoter activity was reduced in exponentially growing *Jun<sup>d/d</sup>* cells compared to wild-type MEFs (Figure 3J). Reduced cyclin D1 expression was further confirmed at the protein level in *Jun<sup>d/d</sup>* cells (Figure 3K). In both mouse and human an AP-1 responsive TRE element (TGT C TCA) has been described in the *cyclin D1* promoter proximal region<sup>41</sup>. ChIP experiments showed that Jun and JunD bound to the TRE element indicating that Jun and JunD directly control the transcription of *cyclin D1* through the TRE promoter site (Figure 3M).

### Reduced EGFR expression in *Jun*<sup>d/d</sup> MEFs

Next we analyzed the role of EGFR, a Jun-target gene playing a major role in fibroblast and keratinocyte proliferation<sup>42</sup>. Expression of *EGFR* mRNA was downregulated, whereas expression of the ligand *HB-EGF* or *TGF- $\alpha$*  was unchanged in *Jun*<sup>d/d</sup> MEFs (Figure 4A). Reduced EGFR expression was further confirmed at the protein level in *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs (Figure 4B). When analyzing potential alternative receptors including other EGFRs, we found that *ErbB2*, *UpaR* and *Igf2R* expression was not changed, whereas *ErbB3* and *ErbB4* expression was not detectable in MEFs (Figure 4C and Supp. Figure 1A). Addition of EGF or HB-EGF to fibroblast cultures induced proliferation of *Jun*<sup>d/d</sup> MEFs, but had little effect on *Jun*<sup>-/-</sup> MEFs (Figure 4D). In contrast, pharmacological inhibition of the EGFR pathway induced cell death independent of the genotype. Inhibition of EGFR (20-0.02 $\mu$ m), ErbB2 (20 $\mu$ m) and EGFR-ErbB2-ErbB4 (20 $\mu$ m, 2 $\mu$ m) had either no effect on proliferation or induced cell death (Figure 4E, Supp. Figure 1B, C and data not shown) suggesting that proliferation of MEFs is not affected by EGFR-ErbB2-ErbB4 inhibition.

Besides the mitogenic effect of EGF on *Jun*<sup>d/d</sup> MEFs, high doses of EGF also rescued premature senescence of *Jun*<sup>d/d</sup> cells. During the first 2 passages, cell proliferation was comparable between *Jun*<sup>+/+</sup>, *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs. At passage 4 (d=12), *Jun*<sup>-/-</sup> cells showed significantly reduced proliferation rates (Figure 4F), whereas *Jun*<sup>d/d</sup> cells proliferated almost similar to wild-type cells in the presence of EGF. This indicates that different molecular targets are responsible for the proliferation defects of these two cell populations. EGFR was not phosphorylated in *Jun*<sup>-/-</sup> cells under any condition tested, whereas *Jun*<sup>d/d</sup> cells displayed phosphorylated EGFR after treatment

with 10x EGF at tyrosine 1173 and tyrosine 1068 (100ng/ml) (Figure 4G). Consistent with defective EGFR phosphorylation, the down-stream kinases Akt and GSK-3 $\beta$  were not phosphorylated by either 20% FCS or high doses of EGF in *Jun*<sup>-/-</sup> cells (Figure 4H). In contrast, induction of Akt and GSK-3 $\beta$  phosphorylation was observed in *Jun*<sup>d/d</sup> cells after treatment with 10xEGF (Figure 4H). In contrast, ERK1/2 and JNK1/2 activation was similar in all cells analyzed (Figure 4H and data not shown). Furthermore, phosphorylation of p38 MAPK was found to be moderately increased in *Jun*<sup>-/-</sup> MEFs (Figure 4H). *Cyclin D1* induction in *Jun*<sup>d/d</sup> cells upon 10xEGF treatment reached similar levels to wild-type MEFs (Figure 4I).

Together, *Jun*<sup>d/d</sup> MEFs have limited capacity of replication, which is caused by inefficient Jun-dependent gene transcription that can be activated by an Akt-signaling cascade upon response to growth factors, such as EGF or HB-EGF. The reduction and delay in *cyclin D1* expression might contribute to the senescence phenotype, whereas this pathway is not active in the absence of Jun possibly due to upregulated p38 activity.

### **Increased oxidative stress in *Jun*<sup>-/-</sup> MEFs and fetal livers is rescued by JunD**

JunD was identified to play an important role in regulating oxidative stress by controlling H<sub>2</sub>O<sub>2</sub> levels<sup>14</sup>, we next analyzed oxidant toxicity in *Jun*<sup>d/d</sup> MEFs and fetal liver cells. H<sub>2</sub>O<sub>2</sub> production was found to be increased in *Jun*<sup>-/-</sup> and *Jun*<sup>d/d</sup> MEFs (Figure 5A). Addition of antioxidants, such as ascorbate (vitamin C) or chemical antioxidants like butylated hydroxyanisole (BHA) and N-acetyl-L-cysteine (NAC) had no effect on cell proliferation of *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs (Figure 5B).

The expression of *Nrf1* and *Nrf2* was next analyzed, since these transcription factors are involved in regulating the redox balance<sup>39</sup>. Low levels of *Nrf1* and *Nrf2* were observed in both *Jun*<sup>-/-</sup> and *Jun*<sup>d/d</sup> MEFs (Figure 5C) compared to wild-type MEFs. As reported<sup>43</sup>, low levels of *Glutamate-cysteine ligase, catalytic subunit (Gclc)* and glutathione (GSH) synthase (*Gss*), key enzymes responsible for maintaining GSH homeostasis were found to be expressed at similar levels in *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs, although the difference was not significant (Figure 5C). *Glutamate-cysteine ligase, modifier subunit (Gclm)* and the JunD target genes *Nox4*, *Cdo1* and *Mgst1* were found to be expressed at similar levels in *Jun*<sup>-/-</sup> and *Jun*<sup>d/d</sup> MEFs (Figure 5C). Interestingly, *Nrf1* and *Gss* expression in *Jun*<sup>d/d</sup> cells was almost restored to wild-type levels upon EGF treatment, while expression was weakly induced in *Jun*<sup>-/-</sup> MEFs (Figure 5D and data not shown). Next we asked whether the defect in H<sub>2</sub>O<sub>2</sub> production and *Nrf1/2* expression is cell-type dependent. Secretion of H<sub>2</sub>O<sub>2</sub> in *Jun*<sup>d/d</sup> fetal liver cells was found to be similar to wild-type levels (Figure 6A). However, increased H<sub>2</sub>O<sub>2</sub> secretion was observed in Jun-deficient fetal liver cells (Figure 6A). Jun target genes, such as p53 and p21, were undetectable at the protein level in any of the fetal liver extracts analyzed. Interestingly, expression of *Nrf1*, *Nrf2*, *Gclc* and *Gss* was downregulated in *Jun*<sup>-/-</sup> fetal liver cells, but rescued by JunD (Figure 6C). There was no difference in expression of the JunD target genes *Nox4*, *Cdo1* and *Mgst1* (Figure 6C). Thus, JunD can rescue the oxidative stress response in fetal liver cells lacking Jun, but not in MEFs, suggesting that this phenotype is cell-type specific.

## Discussion

In this study we demonstrate that JunD can partially substitute for Jun-specific functions in embryonic development, such as fetal liver development to birth. Jun-deficient fetal livers secreted high levels of H<sub>2</sub>O<sub>2</sub>, which was rescued by JunD expression in *Jun<sup>d/d</sup>* cells. *In vitro*, JunD was not able to substitute for Jun in cell proliferation of MEFs, and *Jun<sup>d/d</sup>* cells underwent early senescence, secreted increased H<sub>2</sub>O<sub>2</sub> levels, expressed reduced levels of EGFR, and exhibited defective EGF-dependent signal transduction. These properties of *Jun<sup>d/d</sup>* cells are reminiscent of primary MEFs lacking Jun. However, all defects of *Jun<sup>d/d</sup>* cells could be overcome by addition of EGF and HB-EGF, whereas *Jun<sup>-/-</sup>* MEFs did not respond to growth factor stimulation. Thus, JunD regulation of specific target genes is strongly dependent on the cellular context (Figure 6D).

When JunD was expressed from the Jun locus, some fetuses developed to birth, showed normal liver architecture, but displayed severe cardiac defects, as previously described for a JunB knock-in gene substitution of Jun<sup>17</sup>. Besides these similarities, several differences were observed. First, all *Jun<sup>d/d</sup>* newborns died immediately after birth, whereas JunB knock-in mice survived until postnatal day 4. In addition, 50% of *Jun<sup>d/d</sup>* embryos died around E12.5 displaying defects in neurulation and growth retardation. However, JunD - like JunB - can fully compensate for the lack of Jun in fetal liver development, since impaired proliferation and increased apoptosis of Jun-deficient fetal livers was fully rescued *in vivo*. Conversely, a functional *Jun* gene is essential for proper heart development, since neither JunB nor JunD, when expressed from the Jun locus, rescued the heart malformation. In contrast, Jun-deficient mice ectopically expressing a

JunB transgene are born without liver and heart defects<sup>17</sup>. In addition, a JunB transgene is also sufficient to bypass embryonic lethality observed in *Junb*<sup>-/-</sup> embryos<sup>17, 18</sup>. JunD does not have the ability to rescue both Jun-dependent liver and heart defects in a gene-dosage dependent manner. *Jund* transgenic mice<sup>27</sup> in a *Jun*<sup>-/-</sup> background did not develop beyond E15.5, possibly due to different JunD functions in activating/repressing specific target genes (data not shown). This implies that the physiological functions of the structurally similar proteins JunB and JunD partially overlap.

*Jun*<sup>d/d</sup> MEFs displayed premature senescence and impaired proliferation similar to MEFs lacking Jun. The defect in proliferation was not caused by increased JunD expression as deletion of endogenous JunD in *Jun*<sup>d/d</sup> cells also resulted in senescence and in complete cell cycle block (data not shown). The fact that both JunD and Jun bind to the *p53* promoter supports the notion that JunD is capable of suppressing *p53* transcription. This is supported by our previous studies demonstrating that Jun is a major AP-1 component mediating negative regulation of the *p53* promoter site PF1<sup>21</sup>. Importantly, *cyclin D1* expression was greatly reduced in *Jun*<sup>d/d</sup> MEFs compared to wild-type cells. ChIP experiments indicate that apparently all Jun members can influence *cyclin D1* transcription by binding to the TRE site in the *cyclin D1* promoter. Interestingly, replacement of Jun by JunB rescued the cellular defects associated with loss of Jun<sup>17</sup>, since these MEFs do not enter premature senescence. Notably, both p16 and cyclin D1 expression was increased in *Jun*<sup>b/b</sup> cells.

Imbalanced Akt signaling contributed to the resistance of cells to EGF. Indeed, insufficient Akt and GSK-3 $\beta$  phosphorylation upon serum stimulation was completely restored in *Jun*<sup>d/d</sup> cells using increasing EGF concentrations indicating that an EGFR-

dependent signal is necessary for effective activation. A regulatory loop from EGFR signaling to Jun-dependent EGFR expression has been described<sup>42</sup>. A decrease in EGFR expression and EGFR signaling was observed in *Jun*<sup>d/d</sup> MEFs and cells lacking Jun. EGFR activates the cyclin D1 gene<sup>44</sup>. EGFR and Jun play also a prominent role in regulating embryonic eyelid closure. JunD and JunB knock-in mice are born with open eyes, similar to defects observed in mice lacking Jun specifically in the epidermis or disruption of the EGFR<sup>42, 45</sup>. This failure was associated with reduced EGFR expression, supporting an EGFR-dependent signaling pathway to regulate gene expression through AP-1.

*Jun*<sup>d/d</sup> cells responded to EGF or HB-EGF stimulation. In contrast, MEFs lacking Jun did not respond to growth factor treatment and EGFR and Akt phosphorylation were still impaired. In developing *Drosophila* eye, low EGFR activity maintains quiescence, similar senescence where EGF responsiveness and binding is lost and EGFR expression decreases with age<sup>46</sup>. In addition, reduced EGFR phosphorylation has been observed in senescent cells compared to proliferating cells<sup>47</sup>. However, the single defect in EGFR expression might not be the main cause of senescence, since MEFs lacking EGFR do not show an obvious proliferation defect (unpublished data). Expression of other EGFR family members was not affected in *Jun*<sup>-/-</sup> fibroblasts nor did pharmacological inhibition of the EGFR pathway interfere with proliferation. EGF treatment did activate p38 activity which was slightly prolonged in *Jun*<sup>-/-</sup> MEFs. Activation of p38 can also result in premature senescence of MEFs<sup>48-50</sup>. Importantly, inhibition of the p38 pathway in *Mkk7*<sup>-/-</sup> cells rescued these cells from premature senescence<sup>51</sup>. Thus, a combined effect of defective EGFR signaling, prolonged p38 expression, increased p53 and p21, and

reduced CDC2 protein levels, may be responsible for the response of *Jun*<sup>-/-</sup> cells to certain growth factors. JunD apparently rescues the endogenous *Jun* promoter upon high EGF treatment through restoration of Jun/AP-1 dependent factors.

Deficiencies in H<sub>2</sub>O<sub>2</sub> metabolism were observed in Jun-deficient fetal livers and MEFs. JunD rescued H<sub>2</sub>O<sub>2</sub> defects in fetal livers, but not in MEFs. Jun and Nrf1 mutant mice display similar phenotypes, such as embryonic lethality and impaired liver degeneration<sup>28</sup> suggesting that these transcription factors may have overlapping, but non redundant functions. On the other hand, JunD and Nrf2 mutant mice are viable, and these transcription factors seem to regulate oxidative stress tolerance and longevity<sup>15, 37, 38, 52, 53</sup>. Thus, Jun and JunD have the ability to protect multiple tissues by regulating detoxification and antioxidant genes as well as cell type-specific targets similar to what has recently been reported for Nrf1/Nrf2<sup>39</sup>. However, *Nrf1* may be more critical for detoxification, as *Nrf2* and expression of other detoxification enzymes is strongly dependent on the genetic background (data not shown). Moreover, Nrf3 has been described to be highly expressed in the placenta<sup>54</sup>; thus, it is tempting to speculate that *Nrf3* and *Junb* may cooperate in the development of the placenta.

In summary, JunB and JunD can substitute for Jun in embryonic development. However, Jun functions in fibroblast proliferation and senescence are not substituted by JunD. Strong genetic and biochemical evidence supports an antagonistic function for Jun and JunB in cell proliferation. This is likely explained by the differences in the transcriptional activities of Jun and JunB and their respective target genes. On the other hand, JunD is a weaker transactivator, exhibits lower DNA binding and is atypically expressed<sup>55</sup>. JunD is likely to bind to different partners than Jun, and differences in dimer

composition might therefore explain why JunB can rescue proliferation, but not JunD. Moreover, JunD is a JNK substrate<sup>56</sup>, whereas JunB is not, although impaired N-terminal phosphorylation might not be the reason for incomplete rescue, since Jun<sup>AA</sup> mice are viable and develop normally<sup>16</sup>. JunD does differ also from Jun and JunB as it is not subjected for ubiquitin-mediated degradation<sup>55</sup>. Thus, prolonged binding and stability of JunD might affect activation or repression of specific target genes. Therefore, Jun, JunB and JunD are not functionally equivalent and as demonstrated have both overlapping and independent functions. This study identified a novel mechanism how Jun proteins and EGFR signaling control cellular proliferation, cell cycle arrest/senescence and the response to stress.

## Material and Methods

### Gene targeting and generation of knock-in mice

The JunD genomic DNA was amplified by PCR, sequence verified, and was cloned into the Jun-mini locus vector<sup>16</sup>. R1 embryonic stem (ES) cells were electroporated with 10 µg of the Not-I linearized knock-in construct and cells were screened for homologous recombination. Four correctly targeted clones out of 1000 analyzed were identified by PCR and Southern analyses as previously described<sup>16, 17</sup>. Mouse chimeras were generated by injecting correctly targeted ES cell clones into C57/BL6 blastocysts and germline transmission was obtained from two independent clones (2H4, 11C11). Heterozygous knock-in mice (*Jun*<sup>d/+</sup>) were maintained in a mixed 129 (sv) x C57/BL6 genetic background. Heterozygous mice were then bred to a general Cre-Deleter. *Jund*<sup>-/-</sup> mice used in this study have been previously described.<sup>10</sup>

### Histology

Fetuses and tissues were fixed in 4% formaldehyde in PBS, embedded in paraffin, 5 µm sectioned and stained either with H&E according to standard procedures or processed further. Immunohistochemical staining for Ki67 (Novocastra) was performed using the ABC staining kit (Vector Laboratories) according to the manufacturer's recommendations. Apoptosis was measured by TUNEL (terminal deoxyribonucleotide transferase mediated dUTP nick end-labeling staining) using an *in situ* Cell Death Detection Kit (Roche).

### **Isolation, growth and transfection of primary mouse embryonic fibroblasts**

MEFs were prepared from wildtype, *Jun*<sup>-/-</sup> and *Jun*<sup>d/d</sup> E12.5 fetuses. 2-4 independent MEF lines per genotype were used for the studies. MEFs were cultured in Dulbecco's modified Eagles medium (DMEM) containing 10% FCS, 2 mM L-glutamine and 100U/ml penicillin/streptomycin. Cells at 70% confluence were arrested by serum deprivation for 48 h in medium containing 0.5% serum and stimulated to re-enter cell cycle by adding medium containing 20% serum or the indicated doses of EGF (Roche). For proliferation assays, MEFs were plated at a density of  $3.75 \times 10^5$  per 25-cm<sup>2</sup> flask and passaged every 3-4 d at the same density to determine the cumulative cell number. Senescence  $\beta$ -galactosidase staining kit protocol was used (Cell Signaling). For rescue experiments, embryonic MEFs were seeded at a density of  $4 \times 10^5$  supplemented with growth factors HB-EGF (Sigma) and EGF (Roche) or with antioxidants ascorbate (Vitamin C; Sigma), butylated hydroxyanisole (BHA; Sigma), and N-Acetylcystein (NAC; Calbiochem) as indicated in the Figure. For EGFR inhibitor experiments, fibroblasts were seeded at a density  $1 \times 10^5$  per 6-well overnight, inhibitors were added the next day, and cells were counted 2 days later. The following EGFR inhibitors were used: EGFR inhibitor (Calbiochem 324674), Erb-B2 inhibitor II (Calbiochem 324732), and EGFR/ErbB-2/ErbB-4 inhibitor (Calbiochem 324840).

The reporter constructs were transfected into *Jun*<sup>+/+</sup>, *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs by employing the Lipofectamine Plus Reagent (Life Technologies). Each transfection was performed in triplicate in 24-well plates and the Renilla luciferase reporter pRL-SV40 (Promega) was cotransfected as an internal control. Promoter luciferase reporter constructs used in the study include: p53 (p53-promo-luc)<sup>21</sup>, *cyclin D1* (cD1-promo-luc)

<sup>25</sup>. Cells were harvested 24 hr after transfection, or starved in 0.5% FCS overnight and restimulated for 8 hr. Cell extracts were prepared and the Luciferase activity was measured according to the Dual-Luciferase™ Reporter Assay System (Promega). All Firefly luciferase reporter activities were normalized for transfection efficiency by determining the ratio between Firefly and Renilla luciferase activity. The mean ± standard deviation is shown.

### **RNA and protein analyses**

Total RNA was isolated using Trizol reagent (GIBCO-BRL) or PerfectPure RNA tissue kit (5Prime), cDNA synthesis was performed as recommended by the Ready-To-Go™-You-Prime-First-Strand Beads Kit from Amersham Biosciences. PCR amplifications were performed under standard conditions. Primer sequences are available upon request. Gene expression of gene markers and controls were analyzed by real-time PCR using BioRad icycler™. For each sample, expression of the Hprt, tubulin or actin gene was used to normalize the amount of the investigated transcript. Protein extracts and Western blot analyses were performed according to standard procedures using 20µg of whole cell extracts. The following antibodies were used in this study: anti-JunD antibody (kind gift of D. Lallemand; M. Yaniv), monoclonal anti-Jun (Transduction Lab), p53, p21 p16, CDC2, CDK2, CDK4, Cyclin A, Cyclin D1, Cyclin E, phospho-EGFR (Tyr 1173), (all from Santa Cruz); phospho-EGFR (Tyr1068), Akt, phospho-Akt, GSK-3 beta, phospho-GSK-3 beta, p42/p44 ERK, phospho-p42/p44-ERK, p38, phospho-p38, JNK, phospho-JNK, EGFR (all from Cell-Signaling); anti-actin (A2066; Sigma). Proteins were visualized by ECL (Amersham Biosciences).

**ChIP experiment.** Chromatin immunoprecipitations were done as recommended (Milipore). The ChIP primers binding in the *cyclin D1* and *p53* promoter region are described in Supplementary Methods. c-Jun antibody (Santa Cruz; H-79), JunB antibody (Santa Cruz ; N-70), JunD antibody (Santa Cruz, 329) and immunoglobulin G (Santa Cruz) was used as unspecific isotype control.

### **Fetal hepatoblasts cultures**

Fetal livers were dissected from wildtype, *Jun*<sup>-/-</sup> and *Jun*<sup>d/d</sup> E12.5 fetuses, mechanically dissociated and plated in DMEM containing 10% FCS, 2 mM glutamine, 1% penicillin/streptomycin and 0.1 mM β-mercaptoethanol. Adherent fetal hepatoblasts were cultivated for seven days with daily medium change to remove non-adherent hematopoietic cells. At least 2-3 independent fetal livers per genotype were used for the studies.

### **Hydrogen peroxide colorimetric assay**

Fibroblasts or fetal liver cells were cultivated as described and culture supernatants were harvested to measure H<sub>2</sub>O<sub>2</sub> levels by ELISA (Sigma). In brief, particles were removed by centrifugation and diluted supernatant (50 mM phosphate, pH 6.0) was incubated with a xlenol orange solution in an acidic solution with sorbitol and ammonium iron sulfate that reacts to produce a purple colour in proportion to the concentration of H<sub>2</sub>O<sub>2</sub> in the sample being tested. The optical density was measured after incubation for 30 minutes at room temperature using a microplate spectrophotometer set to 550 nm (SLT, Spectra Imager).

## **Statistical Analyses**

Data in bars represent averages  $\pm$ s.d. Differences were analyzed by the Student's Test and P values  $<0.05$  were considered significant.

## **Acknowledgements**

We are very grateful to Drs. Latifa Bakiri, Peter Hasselblatt, Maria Sibilia, John Trichereau for critical comments and suggestions to the manuscript; Hannes Tkadletz for help in preparing the illustrations. The IMP is funded by Boehringer Ingelheim and this work was supported by grants from the Research Training Network (RTN) Program of the European Community. J.M.P and A.M are funded by GEN-AU "Austromouse" grant and IMBA by the Austrian Academy of Sciences. E.F.W. is funded by the BBVA-Foundation and L.K. by FWF grant P-18478-B12.

## Titles and legends to figures

### Figure 1. Generation of $Jun^{d/d}$ knock-in mice

(A) Schematic drawing of the targeting strategy used to insert a *Jund* gene into the *Jun* locus. *Jun* coding sequences are indicated by a white box, *JunD* coding sequences by a red box. Homologous recombination between the dashed lines generates the mutant  $Jun^{PGK\beta geo:d/+}$  allele. Using the TRAP-*cre* deleter strain, heterozygous  $Jun^{d/+}$  mice were generated by germline deletion of the floxed  $PGK\beta geo$  allele. DT $\alpha$  corresponds to diphtheria toxin  $\alpha$ , the probe used for Southern blot is shown by a black box and *loxP* sites are depicted by triangles. (B) Southern blot analysis of  $Jun^{PGK\beta geo:d/+}$  ( $Jun^{PGK}$ ) ES cell genomic DNA digested with *Pst*I. Genotypes and positions of the expected bands are indicated. (C) Genotype analysis of progeny from a heterozygous ( $Jun^{d/+}$ ) intercross. PCR analysis was performed by using primers *lox5* and *lox6* shown in (A). Genotypes and positions of the expected wild-type (wt; 380 bp) and mutant ( $Jun^d$ ; 440 bp) bands are indicated. (D) Expression pattern of *Jun*, *Jund* and *Junb* mRNAs isolated from  $Jun^{+/+} Jund^{+/+}$  and  $Jun^{d/+} Jund^{-/-}$  3-wk mouse tissues by RT-PCR analysis. *Actin* serves as a loading control.

### Figure 2. Histological analyses of $Jun^{d/d}$ embryos and genetic complementation with $Jund^{-/-}$ mice

(A) Phenotypic appearance of a newborn wild-type ( $Jun^{+/+}$ ) and  $Jun^{d/d}$  littermate. The open eyes are indicated by an asterisk. (B)  $Jun^{+/+}$  E12.5 embryo (left) and  $Jun^{d/d}$  mutant embryo (right) with neural tube closure defects indicated with arrowheads at E12.5. (C)

Histological sections of E18.5 embryos showing the absence of eyelid fusion (asterisks) in *Jun*<sup>d/d</sup> embryos. Scale bar, 400  $\mu$ m. **(D)** Normal right ventricular outflow tract and aorta (ao; arrows) at E18.5. The outflow in the *Jun*<sup>d/d</sup> embryos tract forms a single vessel (truncus arteriosus communis), before dividing into aorta and pulmonary artery (pa; arrows). Scale bar, 400  $\mu$ m. **(E)** Liver sections of E18.5 *Jun*<sup>+/+</sup> and *Jun*<sup>d/d</sup> littermates. Scale bar, 100  $\mu$ m. **(F)** Liver sections of E12.5 *Jun*<sup>+/+</sup> and *Jun*<sup>d/d</sup> littermates. Scale bar, 50  $\mu$ m. **(G)** Quantification of Ki67-positive cells in *Jun*<sup>+/+</sup> and *Jun*<sup>d/d</sup> liver sections. **(H)** Macroscopic analysis of an E15.5 *Jun*<sup>d/d</sup>*Jund*<sup>-/-</sup> and littermate and embryo.

**Figure 3. Premature senescence of *Jun*<sup>d/d</sup> MEFs**

**(A)** Proliferation rates of MEFs. Cumulative cell number of primary cells from *Jun*<sup>+/+</sup>, *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> cells passaged at 4 day intervals. Arrows indicate the passage number (n=4). **(B)**  $\beta$ -galactosidase activity in *Jun*<sup>d/d</sup> cells that is present only in senescent cells. **(C)** Proliferation rates of *Jun*<sup>+/+</sup>, *Jun*<sup>d/d</sup>*Jund*<sup>-/-</sup> and *Jun*<sup>d/d</sup>*Jund*<sup>-/-</sup> MEFs passaged at 4 day intervals and cumulative cell numbers. Arrows indicate the passage number (n=3). **(D)**  $\beta$ -galactosidase activity is also present in *Jun*<sup>d/d</sup>*Jund*<sup>-/-</sup> MEFs. **(E)** Luciferase reporter assays performed in *Jun*<sup>+/+</sup>, *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> exponentially growing MEFs transfected with the *p53*-luc promoter luciferase constructs (n=3). **(F)** qPCR analysis of *p53* expression in exponentially growing MEFs. **(G)** *p53* protein levels in exponentially growing (ex), serum-starved (st), and serum-stimulated (sti) *Jun*<sup>+/+</sup>, *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs (n = 2-4); Actin serves as loading control. **(H)** RT-PCR analysis (upper panel) of the indicated genes upon UV-induction (40J) in *Jun*<sup>+/+</sup> and *Jun*<sup>d/d</sup> MEFs. *p53* and *p21* protein induction (lower panel) upon UV-induction (40J) in *Jun*<sup>+/+</sup> and *Jun*<sup>d/d</sup> MEFs (n=2). **(I)** *Cdc2*

expression in  $Jun^{+/+}$ ,  $Jun^{d/d}$  and  $Jun^{-/-}$  passage 4 exponentially growing MEFs; Actin serves as a loading control. **(J)** Luciferase reporter assays performed in  $Jun^{+/+}$ ,  $Jun^{d/d}$  and  $Jun^{-/-}$  MEFs transfected with the *cyclin D1*-luc promoter luciferase construct. (n=3) Error bars represent s.d.; asterisk,  $P<0.05$ . **(K)** Serum induction of *cyclin D1* RNA and protein in serum-starved (stv) and serum-stimulated  $Jun^{+/+}$  and  $Jun^{d/d}$  (upper panel) and  $Jun^{+/+}$  and  $Jun^{-/-}$  MEFs (lower panel). *Actin* expression or actin serves as a loading control (n =2-3). Schematic illustration of the mouse *p53* promoter showing the PF1 (TGA C TCT, black circle) binding site<sup>40</sup> **(L)** and mouse *Cyclin D1* promoter **(M)** showing the TRE element (TGT C TCA, red circle)<sup>41</sup>. Arrows indicate primers amplifying proximal fragments. bp, base pairs. Chromatin of the indicated genotypes was immunoprecipitated with Jun antibodies. Endpoint qPCR-amplified fragments are shown. IgG was used as isotype specific antibody control. +/+,  $Jun^{+/+}$ ; -/-,  $Jun^{-/-}$ ; d/d,  $Jun^{d/d}$ ;

**Figure 4. Role of EGFR and Akt signaling in  $Jun^{d/d}$  and  $Jun^{-/-}$  MEF proliferation**

**(A)** qPCR measuring *EGFR* and EGFR ligands (*HB-EGF* and *TGF- $\alpha$* ) in primary  $Jun^{+/+}$ ,  $Jun^{d/d}$  and  $Jun^{-/-}$  MEFs (n =4). **(B)** Western blot of primary MEFs demonstrating reduced expression of EGFR in exponentially growing  $Jun^{d/d}$  (upper panel) and  $Jun^{-/-}$  MEFs (lower panel). **(C)** *ErbB2*, *ErbB3*, *ErbB4*, *UpaR* and *Igf2R* mRNA in  $Jun^{+/+}$ ,  $Jun^{d/d}$  and  $Jun^{-/-}$  MEFs (qPCR, wild type set to 1, n = 3). n.d., not detectable; **(D)** Proliferation of MEFs treated with different concentration of EGF or HB-EGF. 1xEGF (10ng/ml); 10xEGF (100ng/ml); HB-EGF (10ng/ml) (n=4). **(E)** MEFs were treated with inhibitors against ErbB2 (20  $\mu$ M), ErbB2-ErbB4-EGFR (2-4-E; 20 $\mu$ M) and EGFR (20 $\mu$ M, 0.2 $\mu$ M) for 48 hr followed by quantification of cell numbers (n=3). **(F)** Proliferation rates of

*Jun*<sup>+/+</sup>, *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs upon addition of 10xEGF (100ng/ml) passaged at 4 day intervals. Arrows indicate the passage number (n =4). **(G)** Western blot of primary MEFs showing that EGFR is phosphorylated only upon stimulation with 10xEGF (100ng/ml) in *Jun*<sup>d/d</sup> cells. MEFs were starved for 48 hr in 0.5% serum and stimulated for the indicated times with 20% FCS or 10xEGF. **(H)** Akt, GSK-3 $\beta$ , Erk, JNK and p38 activation in primary MEFs upon stimulation as described in (G). **(I)** Serum-starved MEFs were treated with 20%FCS or 10xEGF for 8 hr, followed by qPCR analyses for *cyclin D1* (n=2). Error bars represent s.d.; asterisk,  $P<0.05$ .

**Figure 5. Increased oxidative stress in *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs**

**(A)** Increased secretion of H<sub>2</sub>O<sub>2</sub> measured by ELISA in exponentially growing *Jun*<sup>d/d</sup> and *Jun*<sup>-/-</sup> MEFs (n=3). **(B)** Proliferation of MEFs in the presence of ascorbate (Vit C; 2.5 $\mu$ M), BHA (100 $\mu$ M) or N-Acetyl-cysteine (NAC, 20 mM). Relative cell numbers measured at day 0 and after for 4 days (n=3). **(C)** JunD does not rescue decreased *Nrf1* and *Nrf2* expression in *Jun*<sup>-/-</sup> MEFs (n=4). The relative mRNA expression of *Nrf1/2* and *Nrf1/2* targets in primary *Jun*<sup>+/+</sup>, *Jun*<sup>-/-</sup> and *Jun*<sup>d/d</sup> MEFs (qPCR, wild-type set to 1, n = 4). Error bars represent s.d.; asterisk,  $P<0.05$ . **(D)** Serum-starved MEFs were treated with 10xEGF for 8 hr, followed by qPCR analyses for *Nrf1* and *Gss* (n=2). Error bars represent s.d.; asterisk,  $P<0.05$ .

**Figure 6. Increased oxidative stress in *Jun*<sup>-/-</sup> fetal livers is rescued by JunD**

(A) Elevated H<sub>2</sub>O<sub>2</sub> secretion of *Jun*<sup>-/-</sup> fetal livers is rescued by JunD. H<sub>2</sub>O<sub>2</sub> levels of freshly isolated fetal livers from *Jun*<sup>+/+</sup> and *Jun*<sup>-/-</sup> mice (lower panel) or *Jun*<sup>+/+</sup> and *Jun*<sup>d/d</sup> (upper panel) were determined by a colorimetric ELISA (n=4). (B) p53 and p21 protein expression in *Jun*<sup>-/-</sup> and *Jun*<sup>d/d</sup> fetal livers. *Co*, starved MEF extract; Actin serves as loading control. (C) JunD rescues decreased *Nrf1* and *Nrf2* expression as observed in *Jun*<sup>-/-</sup> fetal livers (n=4). The relative mRNA expression of *Nrf1/2* and *Nrf1/2* targets in primary *Jun*<sup>+/+</sup>, *Jun*<sup>-/-</sup> and *Jun*<sup>d/d</sup> fetal livers (qPCR, wild-type set to 1, n = 4). Error bars represent s.d.; asterisk, *P*<0.05. (D) JunD can substitute for Jun in fetal liver development, but Jun and JunD family members cannot functionally substitute for each other in fibroblast proliferation. The stress response pathway is rescued by JunD, but is dependent on the cellular context.

**Table 1 Genetic analyses of JunD functions *in vivo***

**A. Rescue of *Jun*<sup>-/-</sup> embryonic lethality in *Jun*<sup>d/d</sup> mice <sup>a</sup>**

Stages	Total	<i>Jun</i> <sup>+/+</sup>	<i>Jun</i> <sup>d/+</sup>	<i>Jun</i> <sup>d/d</sup>	Phenotype (A, B, R, N)
E12.5-E13.5	73	24 (33%)	30 (41%)	19 (26%)	(5, 5, 0, 9)
E15.5-18.5	54	15 (28%)	25 (46%)	14 (26%)	(0, 0, 4, 10)
newborn	105	38 (36%)	59 (56%)	8 (8%)	(0, 0, 2, 6)

<sup>a</sup> Intercrosses between *Jun*<sup>d/+</sup> mice. **A**, hindbrain exencephaly; **R**, resorbed embryos; **B**, delayed development; **N**, no obvious anomaly; % = observed frequency.

**B. *Jun*<sup>d/d</sup> embryos lacking JunD <sup>b, c</sup>**

Stages	Total	<i>Jun</i> <sup>+/+</sup> <i>Jund</i> <sup>+/-</sup>	<i>Jun</i> <sup>d/+</sup> <i>Jund</i> <sup>+/-</sup>	<i>Jun</i> <sup>d/d</sup> <i>Jund</i> <sup>+/-</sup>	<i>Jun</i> <sup>+/+</sup> <i>Jund</i> <sup>-/-</sup>	<i>Jun</i> <sup>d/+</sup> <i>Jund</i> <sup>-/-</sup>	<i>Jun</i> <sup>d/d</sup> <i>Jund</i> <sup>-/-</sup>
E12.5-E13.5	38	4 (11%)	8 (21%)	5 (13%)	5 (13%)	11 (29%)	5 (13%)
E15.5-18.5	39	0	0	0	10 (26%)	27 (69%)	2* (5%)

<sup>b</sup> E12.5-E13.5 Intercrosses between *Jun*<sup>+/-</sup>*Jund*<sup>+/-</sup> and *Jun*<sup>+/-</sup>*Jund*<sup>-/-</sup> mice

<sup>c</sup> E15.5-E18.5 Intercrosses between *Jun*<sup>+/-</sup>*Jund*<sup>-/-</sup> and *Jun*<sup>+/-</sup>*Jund*<sup>-/-</sup>; \*, resorbed  
% = observed frequency

## References

1. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. *Immunol Rev* 2005; 208:126-40.
2. Vesely PW, Staber PB, Hoefler G, Kenner L. Translational regulation mechanisms of AP-1 proteins. *Mutat Res* 2009; 682:7-12.
3. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. *Nature Cell Biol* 2002; 4:E131-E6.
4. Hilberg F, Aguzzi A, Howells N, Wagner EF. c-jun is essential for normal mouse development and hepatogenesis. *Nature* 1993; 365:179-81.
5. Johnson RS, van Lingen B, Papaioannou VE, Spiegelman BM. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. *Genes Dev* 1993; 7:1309-17.
6. Behrens A, Sibilio M, David JP, Mohle-Steinlein U, Tronche F, Schutz G, Wagner EF. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. *EMBO J* 2002; 21:1782-90.
7. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, Wagner EF. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. *Cell* 2003; 112:181-92.
8. Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, Rath M, Hui L, Wagner EF. c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. *Genes Dev* 2006; 20:2306-14.
9. Hasselblatt P, Rath M, Komnenovic V, Zatloukal K, Wagner EF. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. *Proc Natl Acad Sci U S A* 2007; 104:17105-10.
10. Thepot D, Weitzman JB, Barra J, Segretain D, Sinnakre M, Babinet C, Yaniv M. Targeted disruption of the murine junD gene results in multiple defects in male reproductive system. *Development* 2000; 127:143-53.
11. Hilfiker-Kleiner D, Hilfiker A, Kaminski K, Schaefer A, Park JK, Michel K, Quint A, Yaniv M, Weitzman JB, Drexler H. Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. 2005; *Circulation*:1470-7.
12. Pillebout E, Weitzman JB, Burtin M, Martino C, Federici P, Yaniv M, Friedlander G, Terzi F. JunD protects against chronic kidney disease by regulating paracrine mitogens. *J Clin Invest* 2003; 112:843-52.
13. Kawamata A, Izu Y, Yokoyama H, Amagasa T, Wagner EF, Nakashima K, Ezura Y, Hayata T, Noda M. JunD suppresses bone formation and contributes to low bone mass induced by estrogen depletion. *J Cell Biochem* 2008; 103:1037-45.
14. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. *Cell* 2004; 17:781-94.
15. Laurent G, Solari F, Mateescu B, Karaca M, Castel J, Bourachot B, Magnan C, Billaud M, Mechta-Grigoriou F. Oxidative stress contributes to aging by enhancing pancreatic angiogenesis and insulin signaling. *Cell Metab* 2008; 7:113-24.
16. Behrens A, Sibilio M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. *Nat Genet* 1999; 21:326-9.
17. Passegue E, Jochum W, Behrens A, Ricci R, Wagner EF. JunB can substitute for Jun in mouse development and cell proliferation. *Nat Genet* 2002; 30:158-66.

18. Schorpp-Kistner M, Wang ZQ, Angel P, Wagner EF. JunB is essential for mammalian placentation. *EMBO J* 1999; 18:934-48.
19. Licht AH, Pein OT, Florin L, Hartenstein B, Reuter H, Arnold B, Lichter P, Angel P, Schorpp-Kistner M. JunB is required for endothelial cell morphogenesis by regulating core-binding factor  $\beta$ . *J Cell Biol* 2006; 175:981-91.
20. Schmidt D, Textor B, Pein OT, Licht AH, Andrecht S, Sator-Schmitt M, Fusenig NE, Angel P, M. S-K. Critical role for Nf- $\kappa$ B-induced JunB in VEGF regulation and tumor angiogenesis. *EMBO J* 2007; 26:710-9.
21. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P, Wagner EF. Control of cell cycle progression by c-Jun is p53 dependent. *Genes Dev* 1999; 13:607-19.
22. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. *EMBO J* 1999; 4:188-97.
23. Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M. The Mammalian UV response: c-Jun Induction is required for Exit from p53-Imposed Growth arrest. *Cell* 2000; 103:897-907.
24. Weitzman JB, Fiette L, Matsuo K, Yaniv M. JunD protects cells from p53-dependent senescence and apoptosis. *Mol Cell* 2000; 6:1109-19.
25. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. *EMBO J* 2000; 19:2056-68.
26. Pfarr C, Mechta F, Spyrou G, Lallemand D, Carillo S, Yaniv M. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. *Cell* 1994; 76:747-60.
27. Meixner A, Karreth F, Kenner L, Wagner EF. JunD regulates lymphocyte proliferation and T helper cell cytokine expression. *EMBO j* 2004; 23:1325-35.
28. Chen L, Kwong M, Lu R, Ginzinger D, Lee C, Leung L, Chan JY. Nrf1 is critical for redox balance and survival of liver cells during development. *Mol Cell Biol* 2003; 23:4673-86.
29. Chan K, Lu R, Chang JC, Kan YW. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. *PNAS* 1996; 93:13943-8.
30. Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M, Reddy SP. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. *Oncogene* 2008; 27:5821-32.
31. Yang H, Magilnick N, Lee C, Kalmaz D, Ou X, Chan JY, Lu SC. Nrf1 and Nrf2 Regulate Glutamate-Cysteine Ligase Catalytic Subunit Transcription Indirectly via NF- $\kappa$ B and Ap-1. *Mol Cell Biol* 2005; 25:5933-46.
32. Beyer TA, Xu W, Teupser D, auf dem Keller U, Bugnon P, Hildt E, Thiery J, Kan YW, Werner S. Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. *EMBO J* 2008; 27:212-23.
33. Chan K, Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice. *Proc Natl Acad Sci U S A* 1999; 96:12731-6.
34. Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. *Proc Natl Acad Sci U S A* 2001; 98:4611-6.

35. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T, Yamamoto M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. *Toxicol Sci* 2001; 59:169-77.
36. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, M Y, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. *Proc Natl Acad Sci U S A* 2001; 98:3410-5.
37. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. *Trends Mol Med* 2004; 10:549-57.
38. Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA. Nrf2, a multi-organ protector? *FASEB J* 2005; 19:1061-6.
39. Ohtsuji M, Katsuoka F, Kobayashi A, Aburatani H, Hayes JD, Yamamoto M. NRF1 and NRF2 play distinct roles in activation of antioxidant response element-dependent genes. *J Biol Chem* 2008; 283:33554-62.
40. Ginsberg D, Oren M, Yaniv M, Piette J. Protein-binding elements in the promoter region of the mouse p53 gene. *Oncogene* 1990; 5:1285-90.
41. Eto I. Molecular cloning and sequence analysis of the promoter region of mouse cyclin D1 gene: implication in phorbol ester-induced tumour promotion. *Cell Prolif* 2000; 33:167-87.
42. Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L, Sibilica M, Wagner EF. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. *Dev Cell* 2003; 4:879-89.
43. Sekhar KR, Meredith MJ, Kerr LD, Soltaninassab SR, Spitz DR, Xu ZQ, Freeman ML. Expression of glutathione and gamma-glutamylcysteine synthetase mRNA is Jun dependent. *Biochem Biophys Res Commun* 1997; 234:588-93.
44. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. *Nat Cell Biol* 2001; 3:802-8.
45. Sibilica M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. *Science* 1995; 269:234-8.
46. Yang L, Baker NE. Cell cycle withdrawal, progression, and cell survival regulation by EGFR and its effectors in the differentiating *Drosophila* eye.. *Dev Cell* 2003; 4:359-69.
47. Brooks KM, Phillips PD, Carlin CR, Knowles BB, Cristofalo VJ. EGF-dependent phosphorylation of the EGF receptor in plasma membranes isolated from young and senescent WI-38 cells. *J Cell Physiol* 1993 1987; 133:523-31.
48. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S, Sun P. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. *Mol Cell Biol* 2002; 22:3389-403.
49. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. *Nat Genet* 2007; 39:741-9.
50. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. *Nat Rev Cancer* 2009; 9:537-49.

51. Wada T, Stepniak E, Hui L, Leibbrandt A, Katada T, Nishina H, Wagner EF, Penninger JM. Antagonistic control of cell fates by JNK and p38-MAPK signaling. *Cell Death Differ* 2008; 15:89-93.
52. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, Hagen TM. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. *Proc Natl Acad Sci U S A* 2004; 101:3381-6.
53. Sykiotis GP, Bohmann D. Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in *Drosophila*. *Dev Cell* 2008; 14:76-85.
54. Chénais B, Derjuga A, Massrieh W, Red-Horse K, Bellingard V, Fisher SJ, Blank V. Functional and placental expression analysis of the human NRF3 transcription factor. *Mol Endocrinol* 2005; 19:125-37.
55. Hernandez JM, Floyd DH, Weilbaecher KN, Green PL, Boris-Lawrie K. Multiple facets of junD gene expression are atypical among AP-1 family members. *Oncogene* 2008; 27:4757-67.
56. Gupta S, Barrett T, Whitmarsh AJ, J. C, H.K. S, B. D, Davis RJ. Selective interaction of JNK protein kinase isoforms with transcription factors. *EMBO J* 1996; 15:2760-70.







Fig.1 Meixner et al.




Fig. 2 Meixner et al.




Fig. 3 Meixner et al.




Fig. 4 Meixner et al.





**A****B****C****D**

Fig. 5 Meixner et al.






Fig. 6 Meixner et al.

**A****B****C**